Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study

The treatment of advanced triple-negative breast cancer, which failed in first-line or second-line therapy, is a significant challenge. We conducted this retrospective study to explore the efficacy and safety of apatinib and capecitabine as the third-line treatment for advanced triple-negative breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yi-Hui, Zhou, Yang, Wang, Yu-Wei, Tong, Ling, Jiang, Run-Xue, Xiao, Lei, Zhang, Guang-Ju, Xing, Shu-Shan, Qian, Fang, Feng, Jing-Qi, Zhao, Ya-Ling, Wang, Jian-Gong, Wang, Xiao-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133618/
https://www.ncbi.nlm.nih.gov/pubmed/30200142
http://dx.doi.org/10.1097/MD.0000000000012222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133618/
https://www.ncbi.nlm.nih.gov/pubmed/30200142
http://dx.doi.org/10.1097/MD.0000000000012222

Ejemplares similares